About FASEB BioAdvances
FASEB BioAdvances is an international open-access journal of FASEB published in partnership with John Wiley and Sons. FASEB BioAdvances serves the global bioscience community by providing a vehicle for publishing well-designed and executed original research, review, and hypothesis papers, as well as reports on the replication of other published work—regardless of perceived or anticipated citation “impact.” Published articles must be of credible design and sound science.
The following article types are considered:
- Original research articles
- Review articles
- Hypothesis articles
- Methods articles
- Articles reporting negative results
- Reproducibility reports that attempt to replicate methods or results from other studies. These papers will be considered for publication based on the validity and integrity of the science regardless of outcome(s).
Meet the Editor
Succeeding Jasna Markovac, PhD, as the founding editor, FASEB BioAdvances named Ralph A. Bradshaw, PhD, as Editor-in-Chief in 2019. Bradshaw is professor emeritus of physiology and biophysics at the University of California, Irvine, and served as FASEB president in 1995-96. He has served on the boards of more than 20 journals. Bradshaw was the founding editor-in-chief of Molecular and Cellular Proteomics; associate editor of the Journal of Biological Chemistry; and founding associate editor of Protein Science. His distinguished research career has focused on polypeptide growth factors and their receptors.
FASEB BioAdvances publishes original, multi/transdisciplinary biomedical research from the international community. Published articles are complete reports judged to be of proper design and execution regardless of results or perceived impact or priority. In addition to reports of new findings, the journal considers articles with confirmatory results.
For more information and to submit a manuscript, visit the FASEB BioAdvances website.